Cataract & Glaucoma Combined Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cataract and glaucoma are two of the most common causes of visual impairment worldwide, and they frequently coexist in the same patient, particularly in the elderly population. A cataract is a progressive clouding of the eye's natural crystalline lens that causes blurred vision, glare sensitivity, and color distortion. Glaucoma is a group of optic neuropathies characterized by progressive damage to the optic nerve, most commonly associated with elevated intraocular pressure (IOP), leading to peripheral visual field loss that can progress to blindness if untreated.

The coexistence of cataract and glaucoma is common because both conditions increase in prevalence with age. Globally, cataracts are responsible for approximately 33% of visual impairment, while glaucoma affects over 80 million people and is the leading cause of irreversible blindness. In patients over age 60, the prevalence of having both conditions simultaneously ranges from 10 to 20%. Additionally, long-term use of topical glaucoma medications and prior glaucoma surgery can accelerate cataract formation.

Combined surgical management of coexisting cataract and glaucoma has evolved significantly with the advent of minimally invasive glaucoma surgery (MIGS) devices and refined surgical techniques. Modern approaches allow ophthalmologists to address both conditions in a single operative session, reducing the total number of surgeries, cumulative recovery time, and the overall burden on the patient. The specific combination of procedures is tailored to the type and severity of glaucoma, the degree of cataract, and individual patient factors.

Combined cataract and glaucoma surgery addresses the simultaneous presence of lens opacity and pathologically elevated intraocular pressure or optic nerve damage. The following conditions are managed through this approach:

• Primary open-angle glaucoma (POAG) with cataract — the most common combination, where trabecular meshwork dysfunction causes elevated IOP alongside age-related lens opacification
• Primary angle-closure glaucoma with cataract — cataract extraction itself opens the drainage angle, and combined glaucoma surgery provides additional IOP control
• Normal-tension glaucoma with cataract — optic nerve damage at statistically normal IOP levels, where further IOP reduction combined with visual rehabilitation is beneficial
• Pseudoexfoliation glaucoma with cataract — accumulation of abnormal fibrillar material that obstructs aqueous outflow and accelerates cataract formation
• Pigmentary glaucoma with cataract — pigment granules from the iris blocking the trabecular meshwork, often coexisting with lens changes
• Steroid-induced glaucoma with cataract — IOP elevation and posterior subcapsular cataract caused by corticosteroid use
• Medication-intolerant glaucoma — patients unable to tolerate topical glaucoma drops who also have visually significant cataracts

The surgical approach varies depending on the specific glaucoma type, the target IOP, the number of medications currently required, and whether the patient has had prior eye surgery or laser treatments.

Candidates for combined cataract-glaucoma surgery are patients who have both a visually significant cataract and glaucoma requiring surgical intervention. The ideal candidate has moderate glaucoma not adequately controlled on maximum tolerated medical therapy (typically 2 or more topical medications) and a cataract that impairs visual function to the point where surgery is warranted. Patients with mild glaucoma on one to two medications who need cataract surgery are excellent candidates for MIGS combined with phacoemulsification.

Patient factors that favor combined surgery include medication non-compliance (difficulty instilling eye drops), intolerance or allergy to topical glaucoma medications, desire to reduce medication burden, and the practical advantage of undergoing one surgical procedure and recovery period rather than two. Patients with angle-closure glaucoma are particularly good candidates, as cataract extraction alone widens the anterior chamber angle and reduces the risk of future angle-closure attacks.

Relative contraindications include active ocular infection or inflammation (uveitis), corneal disease that limits surgical visualization, neovascular glaucoma (which typically requires sequential rather than combined surgery), and advanced glaucoma requiring very low target IOPs that may not be achievable with MIGS procedures. Patients with advanced glaucoma and severe visual field loss may benefit more from a dedicated trabeculectomy or tube shunt rather than a MIGS procedure combined with cataract surgery. Individual risk-benefit assessment by an experienced glaucoma specialist is essential.

Phacoemulsification with MIGS is the most rapidly growing approach for combined surgery. After standard cataract removal via phacoemulsification and intraocular lens (IOL) implantation, a MIGS device or procedure is performed through the same corneal incision. Options include trabecular micro-bypass stents (iStent, iStent inject), Schlemm canal scaffolds (Hydrus Microstent), goniotomy procedures (Kahook Dual Blade, GATT), and subconjunctival microstents (Xen gel stent). MIGS procedures typically reduce IOP by 20 to 30% and decrease medication burden by 1 to 2 drops. They are best suited for mild to moderate open-angle glaucoma.

Phacoemulsification with trabeculectomy (phacotrabeculectomy) combines cataract surgery with the creation of a drainage fistula that allows aqueous humor to drain from the anterior chamber to a subconjunctival filtering bleb. This approach provides more substantial IOP reduction (30 to 50%) and is indicated for moderate to severe glaucoma requiring lower target pressures. The procedure is more complex, carries higher complication rates than MIGS, and requires careful postoperative bleb management with potential use of antimetabolites such as mitomycin C.

Phacoemulsification with tube shunt (phacotrabeculectomy alternative) combines cataract surgery with implantation of a glaucoma drainage device such as the Ahmed or Baerveldt tube. This is reserved for complex or refractory glaucoma cases, prior failed trabeculectomy, or neovascular glaucoma. Phacoemulsification with endocyclophotocoagulation (ECP) uses a laser fiber to reduce aqueous production by treating the ciliary body from inside the eye during cataract surgery. Each approach has specific indications, advantages, and limitations that guide the surgeon's recommendation for individual patients.

Combined cataract-glaucoma surgery offers the significant advantage of addressing two sight-threatening conditions in a single operative session with one recovery period. Visual rehabilitation from cataract removal is typically rapid, with most patients noticing improved clarity, contrast sensitivity, and color perception within days. Simultaneously, the glaucoma component provides sustained IOP reduction that protects the optic nerve from further damage.

Clinical outcomes from combined surgery are well-documented. Phacoemulsification with MIGS devices typically achieves a 20 to 30% reduction in IOP from preoperative levels and reduces the number of glaucoma medications required by an average of 1 to 2 drops per day. Studies of the Hydrus Microstent combined with cataract surgery demonstrate that 78% of patients achieve IOP of 18 mmHg or lower without medications at 2 years. Phacotrabeculectomy achieves greater IOP reduction (30 to 50%) and is effective in achieving target pressures below 15 mmHg when needed for more advanced disease.

The medication reduction achieved through combined surgery significantly improves quality of life by eliminating the burden of multiple daily eye drops, reducing ocular surface disease caused by preservatives in glaucoma medications, and improving medication adherence. Studies consistently show that combined procedures produce IOP-lowering results comparable to standalone glaucoma surgery while simultaneously restoring visual acuity lost to cataract, resulting in high patient satisfaction rates exceeding 85%.

The risk profile of combined cataract-glaucoma surgery depends on the specific glaucoma procedure performed alongside phacoemulsification. MIGS procedures combined with cataract surgery have an excellent safety profile, with complication rates similar to cataract surgery alone. Common minor issues include transient IOP elevation in the first week, mild hyphema (blood in the anterior chamber) that typically resolves within 1 to 2 weeks, and transient corneal edema. Serious complications such as endophthalmitis (intraocular infection) occur in less than 0.1% of cases.

Phacotrabeculectomy carries a higher complication rate reflecting the complexity of bleb surgery. Bleb-related complications include hypotony (excessively low IOP) in 5 to 15% of cases, bleb leaks, encapsulated bleb requiring needling revision, and rarely bleb-related infection (blebitis or endophthalmitis) occurring in 1 to 2% of cases over 5 years. Choroidal effusion, suprachoroidal hemorrhage, and wound leak are uncommon but recognized risks. Tube shunt procedures carry additional risks including tube erosion, diplopia from the plate affecting extraocular muscles, and corneal endothelial damage from the tube.

General cataract surgery risks applicable to all combined procedures include posterior capsule rupture (1 to 3%), retained lens fragments, cystoid macular edema, refractive surprise, and retinal detachment (less than 0.5%). Patients should understand that the glaucoma component of surgery cannot restore vision already lost to optic nerve damage and that continued monitoring and possible additional interventions may be necessary for long-term glaucoma management. Regular postoperative follow-up is essential for early detection and management of any complications.

Recovery from combined cataract-glaucoma surgery requires more intensive postoperative monitoring than cataract surgery alone. Patients are typically examined on postoperative day 1, then at 1 week, 2 weeks, 1 month, 3 months, and 6 months. The postoperative medication regimen includes antibiotic eye drops for 1 to 2 weeks and anti-inflammatory drops (corticosteroid or NSAID) tapered over 4 to 8 weeks. For phacotrabeculectomy patients, the corticosteroid may be continued longer to modulate bleb healing.

Visual recovery follows a pattern similar to cataract surgery alone, with most patients achieving good functional vision within 1 to 2 weeks. However, IOP may fluctuate during the early postoperative period, particularly after trabeculectomy, requiring close monitoring and possible intervention. Bleb management after phacotrabeculectomy may include suture lysis (typically performed at 1 to 4 weeks) to titrate aqueous flow and optimize IOP control. Activity restrictions include avoiding heavy lifting, bending, and strenuous exercise for 2 to 4 weeks, and avoiding swimming or submerging the eye in water for 4 weeks.

Long-term follow-up for the glaucoma component is essential regardless of the surgical technique used. Patients should have IOP measurements, optic nerve evaluation, and visual field testing at regular intervals as determined by their ophthalmologist. Glaucoma medications may need to be restarted if IOP rises above target over time, and additional glaucoma procedures may be necessary. Annual comprehensive eye examinations are recommended lifelong. Patients with IOL implants may eventually develop posterior capsular opacification requiring YAG laser capsulotomy, which does not affect the glaucoma component of treatment.

The cost of combined cataract-glaucoma surgery varies substantially based on the type of glaucoma procedure performed alongside phacoemulsification. MIGS device implantation adds the cost of the device itself (which varies by device type) plus additional operative time. Trabeculectomy and tube shunt procedures increase complexity, operative time, and the need for more intensive postoperative care, all of which increase costs. The choice of intraocular lens (standard monofocal versus premium toric or multifocal) also affects the overall expense.

Additional cost factors include preoperative diagnostic testing (visual field testing, OCT of the optic nerve and retina, gonioscopy, biometry for IOL calculations), the facility fee and anesthesia charges, postoperative medications (which may include multiple eye drops for several weeks), and the increased number of postoperative visits compared to cataract surgery alone. Potential need for additional procedures such as bleb needling or suture lysis adds to the total treatment cost.

Insurance coverage for combined surgery is generally available when medical necessity is documented, as both cataract and glaucoma surgery are medically indicated procedures. However, coverage for specific MIGS devices varies by insurer and region. Premium IOL upgrades are typically patient-pay. Patients pursuing surgery internationally may find substantial savings on the combined procedure, but should plan for adequate follow-up duration at the surgical destination (1 to 2 weeks minimum) and arrange local ophthalmologic follow-up upon return home for ongoing glaucoma monitoring.

Sequential surgery (performing cataract surgery and glaucoma surgery as separate procedures at different times) is an alternative to combined surgery. This approach allows each procedure to be evaluated independently, simplifies postoperative management, and may be preferred when the timing needs of each condition differ. However, it requires two separate surgeries, two anesthesia events, and two recovery periods, and may expose the eye to additional cumulative surgical risk.

Medical management of glaucoma with cataract surgery alone may be appropriate for patients with well-controlled glaucoma on one to two medications who have good compliance and tolerate their drops well. Cataract surgery alone provides a modest 1.5 to 3 mmHg IOP reduction and may allow medication reduction in some patients. This approach avoids the added complexity and cost of a concurrent glaucoma procedure but does not address the underlying aqueous outflow pathology.

Laser treatments offer non-incisional options for both conditions. Selective laser trabeculoplasty (SLT) reduces IOP by 20 to 30% and can be performed before or after cataract surgery as an alternative to combined incisional glaucoma surgery. Laser peripheral iridotomy (LPI) is the primary treatment for angle-closure glaucoma and may be sufficient when combined with cataract surgery. Cyclophotocoagulation (transscleral or micropulse) reduces aqueous production and may be an option for patients who are not good surgical candidates. For cataracts alone, monitoring with regular prescription updates and anti-glare measures may be appropriate if the cataract is not yet significantly affecting vision or daily function.